OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy
Yaniv Kazansky, Daniel Cameron, Helen S. Mueller, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 965-981
Open Access | Times Cited: 18
Yaniv Kazansky, Daniel Cameron, Helen S. Mueller, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 965-981
Open Access | Times Cited: 18
Showing 18 citing articles:
Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 24
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 24
Chromatin remodellers as therapeutic targets
Hayden A. Malone, Charles W.M. Roberts
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 9, pp. 661-681
Closed Access | Times Cited: 11
Hayden A. Malone, Charles W.M. Roberts
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 9, pp. 661-681
Closed Access | Times Cited: 11
Hallmark discoveries in the biology of non-Wilms tumour childhood kidney cancers
Daniela Perotti, Maureen J. O’Sullivan, Amy L. Walz, et al.
Nature Reviews Urology (2025)
Closed Access | Times Cited: 1
Daniela Perotti, Maureen J. O’Sullivan, Amy L. Walz, et al.
Nature Reviews Urology (2025)
Closed Access | Times Cited: 1
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes
Varadha Balaji Venkadakrishnan, Adam G. Presser, Richa Singh, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Varadha Balaji Venkadakrishnan, Adam G. Presser, Richa Singh, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
The stromal microenvironment endows pancreatic neuroendocrine tumors with spatially specific invasive and metastatic phenotypes
Ye Zeng, Qiang Li, Yuheng Hu, et al.
Cancer Letters (2024) Vol. 588, pp. 216769-216769
Closed Access | Times Cited: 5
Ye Zeng, Qiang Li, Yuheng Hu, et al.
Cancer Letters (2024) Vol. 588, pp. 216769-216769
Closed Access | Times Cited: 5
Compound AC1Q3QWB upregulates CDKN1A and SOX17 by interrupting the HOTAIR—EZH2 interaction and enhances the efficacy of tazemetostat in endometrial cancer
Lingli Chen, Xingyu Zheng, Wenlu Liu, et al.
Cancer Letters (2023) Vol. 578, pp. 216445-216445
Open Access | Times Cited: 11
Lingli Chen, Xingyu Zheng, Wenlu Liu, et al.
Cancer Letters (2023) Vol. 578, pp. 216445-216445
Open Access | Times Cited: 11
A novel case of glial transdifferentiation in renal medullary carcinoma brain metastasis
Maria A. Gubbiotti, Ian E. McCutcheon, Priya Rao, et al.
Acta Neuropathologica Communications (2025) Vol. 13, Iss. 1
Open Access
Maria A. Gubbiotti, Ian E. McCutcheon, Priya Rao, et al.
Acta Neuropathologica Communications (2025) Vol. 13, Iss. 1
Open Access
Epigenetic drugs in cancer therapy
Amila Suraweera, Kenneth J. O’Byrne, Derek J. Richard
Cancer and Metastasis Reviews (2025) Vol. 44, Iss. 1
Open Access
Amila Suraweera, Kenneth J. O’Byrne, Derek J. Richard
Cancer and Metastasis Reviews (2025) Vol. 44, Iss. 1
Open Access
Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies
Jinshou Yang, Feihan Zhou, Xiyuan Luo, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Jinshou Yang, Feihan Zhou, Xiyuan Luo, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Curcuminoids WM03 inhibits ovarian cancer cisplatin-resistant cells proliferation and reverses cisplatin resistance by targeting DYRK2
Minjie Zhang, Xiaoxi Wan, Mengna Shi, et al.
Phytomedicine (2025), pp. 156632-156632
Closed Access
Minjie Zhang, Xiaoxi Wan, Mengna Shi, et al.
Phytomedicine (2025), pp. 156632-156632
Closed Access
The Cell Cycle: a Key to Unlock EZH2-targeted Therapy Resistance
Rachel L. Paolini, George P. Souroullas
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 903-905
Closed Access | Times Cited: 3
Rachel L. Paolini, George P. Souroullas
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 903-905
Closed Access | Times Cited: 3
Current Molecular and Clinical Landscape of ATRT – The Link to Future Therapies
Katharina Gastberger, Victoria E. Fincke, Marlena Mucha, et al.
Cancer Management and Research (2023) Vol. Volume 15, pp. 1369-1393
Open Access | Times Cited: 7
Katharina Gastberger, Victoria E. Fincke, Marlena Mucha, et al.
Cancer Management and Research (2023) Vol. Volume 15, pp. 1369-1393
Open Access | Times Cited: 7
Rhabdoid tumor predisposition syndrome: A historical review of treatments and outcomes for associated pediatric malignancies
Sarah Andres, Karen Huang, Margaret Shatara, et al.
Pediatric Blood & Cancer (2024) Vol. 71, Iss. 6
Closed Access | Times Cited: 2
Sarah Andres, Karen Huang, Margaret Shatara, et al.
Pediatric Blood & Cancer (2024) Vol. 71, Iss. 6
Closed Access | Times Cited: 2
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes
Varadha Balaji Venkadakrishnan, Adam G. Presser, Richa Singh, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Varadha Balaji Venkadakrishnan, Adam G. Presser, Richa Singh, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes
Varadha Balaji Venkadakrishnan, Adam G. Presser, Richa Singh, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Varadha Balaji Venkadakrishnan, Adam G. Presser, Richa Singh, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Proximal and classic epithelioid sarcomas are distinct molecular entities defined by MYC/GATA3 and SOX17/endothelial markers, respectively
Luca Sigalotti, Anna Maria Frezza, Marta Sbaraglia, et al.
Modern Pathology (2024) Vol. 38, Iss. 1, pp. 100647-100647
Open Access | Times Cited: 1
Luca Sigalotti, Anna Maria Frezza, Marta Sbaraglia, et al.
Modern Pathology (2024) Vol. 38, Iss. 1, pp. 100647-100647
Open Access | Times Cited: 1
EZH2 inhibition: it’s all about the context
Ezra Rosen, Neerav Shukla, Julia L. Glade Bender
JNCI Journal of the National Cancer Institute (2023) Vol. 115, Iss. 11, pp. 1246-1248
Open Access | Times Cited: 3
Ezra Rosen, Neerav Shukla, Julia L. Glade Bender
JNCI Journal of the National Cancer Institute (2023) Vol. 115, Iss. 11, pp. 1246-1248
Open Access | Times Cited: 3
Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas
Yaniv Kazansky, Helen S. Mueller, Daniel Cameron, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Yaniv Kazansky, Helen S. Mueller, Daniel Cameron, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
